The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Earlier detection of ATTR-CM: identifying patients before severe disease develops
Ilia Davarashvili, MD, Leumit Health Services and Leumit Start, Tel Aviv, Israel, discusses the importance of earlier detection of transthyretin amyloid cardiomyopathy (ATTR-CM). Dr Davarashvili highlights the need to identify ATTR-CM before severe complications develop, emphasizing the importance of timely referral into the appropriate diagnostic pathway to improve patient outcomes. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Today I had a presentation on the COVID complications, cardiovascular complications. A lot of researchers have made great careers and research in the COVID field. I think ATTR is a developing field that in five years a lot of researchers will make a lot of good things and it will make a lot of good things and it will raise up. But how should we apply then and how should we look at that from a side? I think today we are discovering the ATTR-CM patients after getting the clues of the severity of the disease, after they already have atrial fibrillation, conduction disease, recurrent hospitalizations, coming to the tertiary hospital, and afterwards making a combination of, and thinking about the severity of the disease, but we should not discover, we should recognize it a stage before...
Today I had a presentation on the COVID complications, cardiovascular complications. A lot of researchers have made great careers and research in the COVID field. I think ATTR is a developing field that in five years a lot of researchers will make a lot of good things and it will make a lot of good things and it will raise up. But how should we apply then and how should we look at that from a side? I think today we are discovering the ATTR-CM patients after getting the clues of the severity of the disease, after they already have atrial fibrillation, conduction disease, recurrent hospitalizations, coming to the tertiary hospital, and afterwards making a combination of, and thinking about the severity of the disease, but we should not discover, we should recognize it a stage before. In a big healthcare system in asymptomatic and subclinical patients, and this is a game, because we know that the morbidity and mortality rate is very high after they start to be clinically overt, so I think that the message, and the take-home message to your question is that the right patient should be discovered and should start a prompt, right confirmatory pathway at the right time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
